The retinoid X receptor: a nuclear receptor that modulates the sleep-wake cycle in rats.

RATIONALE: The nuclear receptor retinoid X receptor (RXR) belongs to a nuclear receptor superfamily that modulates diverse functions via homodimerization with itself or several other nuclear receptors, including PPARα. While the activation of PPARα by natural or synthetic agonists regulates the sleep-wake cycle, the role of RXR in the sleep modulation is unknown. OBJECTIVES: We investigated the effects of bexarotene (Bexa, a RXR agonist) or UVI 3003 (UVI, a RXR antagonist) on sleep, sleep homeostasis, levels of neurochemical related to sleep modulation, and c-Fos and NeuN expression. METHODS: The sleep-wake cycle and sleep homeostasis were analyzed after application of Bexa or UVI. Moreover, we also evaluated whether Bexa or UVI could induce effects on dopamine, serotonin, norepinephrine epinephrine, adenosine, and acetylcholine contents, collected from either the nucleus accumbens or basal forebrain. In addition, c-Fos and NeuN expression in the hypothalamus was determined after Bexa or UVI treatments. RESULTS: Systemic application of Bexa (1 mM, i.p.) attenuated slow-wave sleep and rapid eye movement sleep. In addition, Bexa increased the levels of dopamine, serotonin, norepinephrine epinephrine, adenosine, and acetylcholine sampled from either the nucleus accumbens or basal forebrain. Moreover, Bexa blocked the sleep rebound period after total sleep deprivation, increased in the hypothalamus the expression of c-Fos, and decreased NeuN activity. Remarkably, UVI 3003 (1 mM, i.p.) induced opposite effects in sleep, sleep homeostasis, neurochemicals levels, and c-Fos and NeuN activity. CONCLUSIONS: The administration of RXR agonist or antagonist significantly impaired the sleep-wake cycle and exerted effects on the levels of neurochemicals related to sleep modulation. Moreover, Bexa or UVI administration significantly affected c-Fos and NeuN expression in the hypothalamus. Our findings highlight the neurobiological role of RXR on sleep modulation.

Sleep and Neurochemical Modulation by DZNep and GSK-J1: Potential Link With Histone Methylation Status.

Histone methylation/demethylation plays an important modulatory role in chromatin restructuring, RNA transcription and is essential for controlling a plethora of biological processes. Due to many human diseases have been related to histone methylation/demethylation, several compounds such as 3-deazaneplanocin A (DZNep) or 3-((6-(4,5-Dihydro-1H-benzo[d]azepin-3(2H)-yl)-2-(pyridin-2-yl)pyrimidin-4-yl)amino)propanoic acid; N-[2-(2-pyridinyl)-6-(1,2,4,5-tetrahydro-3H-3-benzazepin-3-yl)-4-pyrimidinyl]-ß-Alanine (GSK-J1), have been designed to inhibit histone methylase or suppress histone demethylase, respectively. In the present study, we investigated the effects on the sleep-wake cycle and sleep-related neurochemical levels after systemic injections of DZNep or GSK-J1 given during the light or dark phase in rats. DZNep dose-dependently (0.1, 1.0, or 10 mg/kg, i.p.) prolonged wakefulness (W) duration while decreased slow wave sleep (SWS) and rapid eye movement sleep (REMS) time spent during the lights-on period with no changes observed in dark phase. In opposite direction, GSK-J1 (0.1, 1.0, or 10 mg/kg, i.p.) injected at the beginning of the lights-on period induced no statistical changes in W, SWS, or REMS whereas if administered at darkness, we found a diminution in W and an enhancement in SWS and REMS. Finally, brain microdialysis experiments in freely moving animals were used to evaluate the effects of DZNep or GSK-J1 treatments on contents of sleep-related neurochemicals. The results showed that DZNep boosted extracellular levels of dopamine, norepinephrine, epinephrine, serotonin, adenosine, and acetylcholine if injected at the beginning of the lights-on period whereas GSK-J1 exerted similar outcomes but when administered at darkness. In summary, DZNep and GSK-J1 may control the sleep-wake cycle and sleep-related neurochemicals through histone methylation/demethylation activity.

CRISPR/Cas9, the Powerful New Genome-Editing Tool for Putative Therapeutics in Obesity.

The molecular technology known as clustered regularly interspaced palindromic repeats (CRISPR)/CRISPR-associated protein (Cas) is revolutionizing the field of medical research and deepening our understanding of numerous biological processes. The attraction of CRISPR/Cas9 lies in its ability to efficiently edit DNA or modulate gene expression in living eukaryotic cells and organisms, a technology that was once considered either too expensive or scientifically risky. CRISPR/Cas9 has been successfully applied in agriculture to develop the next generation of disease-resistant plants. Now, the capability of gene editing has been translated to the biomedical area, focusing on the future of medicine faced with drug-resistant microbes by selectively targeting genes involved in antibiotic resistance, for example, or finding the ultimate strategy for cancer or HIV. In this regard, it was recently demonstrated that an injection of cancer-fighting CRISPR-modified white blood cells in a patient suffering from metastatic lung cancer could lead to promising results. Researchers and bioethicists are debating questions about the regulation of CRISPR/Cas9 that must be addressed. While legal challenges surround the use of this technique for genetically modifying cell lines in humans, we review the basic understanding of CRISPR/Cas9 and discuss how this technology could represent a candidate for treatment of non-communicable diseases in nutrition, such as obesity.

Fighting obesity: Non-pharmacological interventions.

The abnormal or excessive fat accumulation that impairs health is one of the criteria that fulfills obesity. According to epidemiological data, obesity has become a worldwide public health problem that in turn would trigger additional pathologies such as cardiorespiratory dysfunctions, cancer, gastrointestinal disturbances, depression, sleep disorders, just to mention a few. Then, the search for a therapeutical intervention aimed to prevent and manage obesity has been the focus of study during the last years. As one can assume, the increased prevalence of obesity has translated to search of efficient pharmaceuticals designed to manage this health issue. However, to further complicate the scenario, scientific literature has described that obesity is the result of interaction between multiple events. Therefore, pharmacological approaches have faced a serious challenge for develop the adequate treatment. Here, we argue that a wide range of non-pharmacological/invasive techniques can be used to manage obesity, such as diets, cognitive behavioral interventions, exercise and transcranial direct current stimulation. Combining these techniques may allow improving quality of life of obese patients.

Association between depression severity and executive functioning in late-life depression: a systematic review / Associação entre a severidade dos sintomas depressivos e o funcionamento executivo de idosos com depressão: uma revisão sistemática

OBJECTIVE: Late-life depression is an under-diagnosed and under-treated disease that reduces the well-being of older adults. Executive dysfunction is another critical impairment in elderly depressed individuals which further disrupts their everyday functioning. This systematic review aims to analyze the association between executive function and depression severity in elderly individuals diagnosed with major depressive disorder. METHOD: The studies were retrieved from MEDLINE/PubMed, ISI Web of Knowledge and PsychInfo, after a search strategy combining the terms "depression", "executive function", "neuropsychological assessment", "elderly" and "late life". Study selection, data collection and quality ratings was performed by two independent raters. RESULTS: A total of 1,130 articles were found but only 8 studies met the defined eligibility criteria and evaluated the association between depression severity and executive functioning. Six out of 8 studies found an association between depression severity and executive function, with correlations ranging from small to large (r= -0.15 to -0.53). The included reports had several methodological limitations such as selective data reporting, non-comprehensive executive function assessment and not controlling potential biases. CONCLUSION: Depression severity may be more strongly correlated with a specific set of executive abilities although it also seems to be a broad-based association with executive functioning as a whole. Future high-quality prospective studies are recommended in order to understand the causal relationship between depression severity and executive functioning taking into account possible mediators such as age-related or neurodegenerative cognitive impairment, educational level and other clinic characteristics (e.g. age of onset, medication).

OBJETIVO: A depressão de início tardio é uma doença subdiagnosticada e subtratada que reduz o bem-estar da pessoa idosa. A disfunção executiva é outra alteração crítica em idosos deprimidos, perturbando ainda mais o seu funcionamento diário. Esta revisão sistemática tem como objetivo analisar a associação entre o funcionamento executivo e a severidade dos sintomas depressivos em idosos diagnosticados com transtorno depressivo major. MÉTODOS: Foi realizada uma busca nas bases de dados MEDLINE/PubMed, ISI Web of Knowledge e PsychInfo utilizando os termos "depression", "executive function", "neuropsychological assessment", "elderly" e "late life". A seleção, classificação dos estudos e coleta de dados foram realizadas por dois avaliadores independentes. RESULTADOS: Foram encontrados 1130 artigos, mas apenas 8 estudos preencheram os critérios de elegebilidade. Três avaliaram a associação entre a severidade dos sintomas e o funcionamento executivo. Seis dos 8 estudos encontraram uma associação entre a severidade dos sintomas e o funcionamento executivo, com correlações de diversas magnitudes (r= -0,15 a -0,53). Os artigos incluídos apresentaram várias limitações metodológicas, tais como descrição seletiva de dados, avaliação não compreensiva do funcionamento executivo e falha no controlo de possíveis vieses. CONCLUSÃO: A severidade dos sintomas depressivos pode ser fortemente correlacionada com um conjunto específico de habilidades executivas, embora pareça também existir uma associação mais ampla com o funcionamento executivo como um todo. Recomenda-se a realização de estudos prospetivos com o fim de compreender a relação causal entre a severidade dos sintomas depressivos e o funcionamento executivo, tendo em conta possíveis mediadores tais como défices cognitivos associados ao envelhecimento ou outros processos neuro-degenerativos, nível de escolaridade e outras características clínicas (idade de início da doença, medicação).

Revealing the role of the endocannabinoid system modulators, SR141716A, URB597 and VDM-11, in sleep homeostasis.

The endocannabinoid system comprises receptors (CB1 and CB2 cannabinoid receptors), enzymes (Fatty Acid Amide Hydrolase [FAAH], which synthesizes the endocannabinoid anandamide), as well as the anandamide membrane transporter (AMT). Importantly, previous experiments have demonstrated that the endocannabinoid system modulates multiple neurobiological functions, including sleep. For instance, SR141716A (the CB1 cannabinoid receptor antagonist) as well as URB597 (the FAAH inhibitor) increase waking in rats whereas VDM-11 (the blocker of the AMT) enhances sleep in rodents. However, no further evidence is available regarding the neurobiological role of the endocannabinoid system in the homeostatic control of sleep. Therefore, the aim of the current experiment was to test if SR141716A, URB597 or VDM-11 would modulate the sleep rebound after sleep deprivation. Thus, these compounds were systemically injected (5, 10, 20mg/kg; ip; separately each one) into rats after prolonged waking. We found that SR141716A and URB597 blocked in dose-dependent fashion the sleep rebound whereas animals treated with VDM-11 displayed sleep rebound during the recovery period. Complementary, injection after sleep deprivation of either SR141716A or URB597 enhanced dose-dependently the extracellular levels of dopamine (DA), norepinephrine (NE), epinephrine (EP), serotonin (5-HT), as well as adenosine (AD) while VDM-11 caused a decline in contents of these molecules. These findings suggest that SR141716A or URB597 behave as a potent stimulants since they suppressed the sleep recovery period after prolonged waking. It can be concluded that elements of the endocannabinoid system, such as the CB1 cannabinoid receptor, FAAH and AMT, modulate the sleep homeostasis after prolonged waking.

Cognitive-behavioral therapy for schizophrenia: an overview on efficacy, recent trends and neurobiological findings / Terapia cognitivo-comportamental para esquizofrenia: uma revisão sobre eficácia, avanços recentes e achados neurobiológicos

OBJECTIVE: Cognitive Behavioral Therapy (CBT) has been recommended by several international guidelines as the gold-standard treatment to address the needs of patients with schizophrenia. This review provides an overview on recent advances regarding CBT for schizophrenia. METHODS: An electronic search was performed on PubMed/MEDLINE, Web of Science and Cochrane Database, using the key-words: "schizophrenia", "psychosis", "cognitive-behavioral therapy", "CBT" and "psychotherapy". RESULTS: Numerous systematic reviews support the immediate and long-term efficacy of Cognitive Behavioral Therapy to reduce positive and negative symptoms in patients with schizophrenia. In the last decade, CBT for schizophrenia has been applied to clinical high-risk subjects and delivered using innovative approaches (low intensity, web-based and self-guided). Brain regions and networks which support high-level cognitive functions have been associated with CBT responsiveness. There is preliminary evidence indicating that CBT induces a prefrontal dependent increase in the top-down modulation of social threat activation. CONCLUSION: In the last decade, CBT for schizophrenia has explored new treatment outcomes, targeted acute and pre-clinical populations and provided alternative methods to reach more patients and reduce intervention costs. The patients' neurocognitive profile seems to play a critical role in treatment response and combining CBT with cognitive remediation may allow to enhance therapeutic effects. Although CBT for schizophrenia is widely established as a gold-standard practice, future studies using innovative CBT protocols, exploring brain-related predictors and treatment outcomes may allow this intervention to be more effective, personalized and to reach a wider number of patients.

INTRODUÇÃO: A terapia cognitivo-comportamental (TCC) tem sido recomendada em diversas guidelines internacionais como a intervenção psicoterapêutica padrão de ouro para pacientes com esquizofrenia. Esta revisão tem como objetivo fornecer uma visão global sobre os avanços recentes da TCC na esquizofrenia. MÉTODOS: Para esta revisão narrativa foi realizada uma busca eletrônica na PubMed/MEDLINE, Web of Science e Cochrane Database utilizando as palavras-chave: "schizophrenia", "psychosis", "cognitive-behavioral therapy", "CBT" e "psychotherapy". RESULTADOS: Várias revisões sistemáticas suportam a eficácia da TCC na redução a curto e longo prazo dos sintomas positivos e negativos da esquizofrenia. Na última década, a TCC tem sido aplicada a indivíduos com alto risco de psicose, sendo também exploradas abordagens inovadoras na sua utilização (curta duração, web-based, autogestão). Redes neurais responsáveis por funções cognitivas de nível superior têm sido associadas a respostas positivas após TCC para esquizofrenia. Existe ainda evidência preliminar que a TCC promove a ativação de zonas pré-frontais responsáveis pela modulação top-down face a ameaças sociais. CONCLUSÃO: Na última década, a TCC para esquizofrenia tem explorado novos desfechos, intervindo em populações agudas e pré-clínicas e utilizado métodos alternativos para alcançar mais pacientes e reduzir custos O perfil neurocognitivo dos pacientes aparenta ter um papel crítico na resposta ao tratamento, pelo que combinar a TCC com reabilitação cognitiva poderá potenciar os seus efeitos terapêuticos. Apesar da TCC ser uma prática recomendada para a esquizofrenia, estudos futuros usando protocolos inovadores e explorando preditores e desfechos relacionados com o cérebro poderão possibilitar que esta intervenção seja mais eficaz, personalizável e alcance o máximo número de pacientes possível.

Effects of dual-task interventions on gait performance of patients with Parkinson's Disease: A systematic review / Efeito da dupla tarefa na marcha em pacientes com doença de parkinson: uma revisão sistemática

OBJECTIVE: Parkinson's disease is characterized by motor and non-motor symptoms that impair patients' gait performance, especially while performing dual/concurrent tasks. These deficits impair patients' daily function, because dual-tasking is a crucial ability in terms of everyday living. The aim of this study was to systematically review the effects of dual task interventions on gait performance of patients with Parkinson's disease. METHOD: Studies were retrieved from MEDLINE/PubMed, LILACS and SciELO. We used the PICOS strategy to determine eligibility criteria. The search strategy included an advanced search on the included databases, using the following search query: "Parkinson's Disease" AND "Double Task" OR "Concurrent Tasks" OR "Gait" AND "Walk". Study selection was carried out by two independent researchers and a third one was called when consensus was needed. RESULTS: A total of 188 articles were identified: 169 articles from Medline/PubMed, 10 articles in SciELO, 8 articles in LILACS and 1 item from manual searches. A total of 56 articles were analyzed regarding the eligibility and exclusion criteria based on full text. A final total of 7 studies were included in the systematic review. CONCLUSION: The different types of dual-task interventions reported (dance, sound stimuli, visual and somatosensory) were associated to improvements in several gait performance indicators of Parkinson's disease patients, including gait speed, stride time and length, cadence and step length. External stimuli seem to play a critical role on specific training effects on dual-task gait performance.

OBJETIVO: A Doença de Parkinson é caracterizada por sintomas motores e não motores que prejudicam a marcha, especialmente durante a realização de tarefas duplas/simultâneas. Estes déficits afetam o funcionamento diário do paciente já que a realização de tarefas duplas é uma habilidade crucial para a vida normal.O objetivo deste estudo foi realizar uma Revisão Sistemática sobre os efeitos das tarefas duplas sobre a marcha em pacientes com Doença de Parkinson. MÉTODOS: Os estudos foram recuperados do MEDLINE/PubMed, SciELO e Lilacs. Adotamos a estratégia PICOS para determinar os critérios de elegibilidade. A estratégia de busca foi realizada utilizando uma pesquisa avançada MEDLINE/PubMed, SciELO e Lilacs com os seguintes termos adotados "Doença de Parkinson", "Dupla Tarefa", "Tarefas Concorrentes", "Marcha" e "Caminhada". Operadores booleanos AND e OR foram utilizados para combinação dos termos. A seleção dos estudos foi realizada por dois pesquisadores independentes que, em caso de desacordo, procuraram um consenso sobre a seleção. RESULTADOS: Foram identificados um total de 188 artigos:169 artigos do PubMed/Medline, 10 artigos no SciELO, 8 artigos no LILACS e 1 artigo em buscas manuais. Após uma seleção inicial, 56 artigos foram analisados pelos critérios de elegibilidade e os critérios de exclusão, sendo que um total de sete estudos foi incluído na revisão sistemática. CONCLUSÃO: De acordo com os estudos analisados nesta revisão, os diferentes tipos de intervenção incluídos (dança, estímulos sonoros, visuais e somato-sensoriais) permitem melhorias em vários indicadores de marcha tais como a velocidade, tempo da passada, cadência e comprimento do passo. A utilização de estímulos externos aparentam desempenhar um papel crítico nos efeitos espeíficos do treinamento na marcha em condições de dupla-tarefa.

Aerobic exercise reduces anxiety symptoms and improves fitness in patients with panic disorder / Exercícios aeróbicos reduziram os sintomas de ansiedade e melhoraram o desempenho cardiorrespiratório em portadores de transtorno de pânico

OBJECTIVE: To investigate the effects of a regularly repeated aerobic exercise series on anxiety and maximum oxygen consumption (VO2max) in Panic Disorder patients. METHODS: Ten previously sedentary female subjects diagnosed with Panic Disorder performed 36 sessions of aerobic exercise (at 70 to 75% of VO2max), 3 times per week during 12 weeks. A cardiopulmonary evaluation (ergospirometry test) was used to set the intensity of training as well as to establish baseline and post-training VO2max parameters. The assessment of anxiety symptoms was performed at baseline, at the end of the 6th and 12th weeks, using the Trait Anxiety Inventory (STAI-T) and State Anxiety Inventory (STAI-S), and the Subjective Units of Distress Scale (SUDS) questionnaires. One-way ANOVA for repeated measurements (at 3 moments: Baseline, 6th week (mid-training) and 12th week (post-training) was used to compare the evolution of the questionnaires; the Bonferroni post hoc test was applied to identify differences between moments. A dependent t-test was performed for measures of VO2max. RESULTS: Compared to baseline, (a) STAI-T showed significant anxiety reductions at mid- and post-training moments; (b) STAI-S and SUDS recorded anxiety reductions only at Post-training; (c) VO2max showed a significant improvement at Post-training. CONCLUSION: This protocol promoted beneficial effects on cardiorespiratory fitness and anxiety levels of Panic Disorder patients.

OBJETIVO: O objetivo deste estudo foi investigar os efeitos do exercício aeróbio praticado regularmente sobre a ansiedade e o VO2max em pacientes com transtorno de pânico. MÉTODO: Dez mulheres sedentárias diagnosticadas com transtorno de pânico (TP) realizaram 36 sessões de exercícios aeróbico contínuo (70 a 75% VO2max) em esteira, 3x por semana, durante 12 semanas. Uma avaliação cardiopulmonar (teste ergo-espirométrico) definiu a intensidade do treinamento, bem como estabeleceu valores de VO2max pré e pós-treinamento. A avaliação dos sintomas de ansiedade nos três momentos (controle, 6° e 12° semana), foi realizada utilizando os questionários IDATE-T (Inventário do Traço de Ansiedade), IDATE-S (Inventário do Estado de Ansiedade) e SUDS (Unidades Subjetivas da Escala de Aflição). O teste ANOVA One-way para medidas repetidas (momentos) foi usado para comparar os questionários. O teste Bonferroni post-hoc foi aplicado para identificar as diferenças entre os momentos. As medidas de VO2max foram analisadas através de um teste de "t" dependente. RESULTADOS: Os resultados mostraram redução do IDATE-T na 6° e 12° semanas de exercício; no entanto, o IDATE-S e o SUDS monstraram uma redução apenas na 12° semana. O VO2max apresentou melhora significativa após 12 semanas de intervenção em relação à linha de base. CONCLUSÃO: Conclui-se que o protocolo adotado foi capaz de promover efeitos benéficos sobre a aptidão cardiorrespiratória e sobre os níveis de ansiedade dos pacientes com transtorno de pânico.

Working memory dysfunction in insomniac adults: a systematic metanalytical review / Disfunção da memória de trabalho em adultos insones: uma revisão sistemática

BACKGROUND: Insomnia is the most commonly occurring sleep disorder: recent reports estimate that 25-30% of adults in the general population occasional instances of experience insomnia, while 10% suffer from disturbances severe enough to meet diagnostic criteria for insomnia. Little is known about the mechanisms, causes, clinical course, and consequences of this condition. Over 30 studies have been published on the matter but only a small proportion has found differences in the working memory of individuals with vs. without insomnia. OBJECTIVE: To summarize evidence regarding the differences in working memory performance between insomniac vs. normal adult sleepers. METHODS: The survey was conducted using an advanced search in the ISI Web of Science and MEDLINE/PubMed with the terms "sleep", "insomnia" and "working memory" as major descriptors; these were crossed with the following keywords: "psychological tests", "neuropsychology" and "performance". RESULTS: A total of 112 articles were identified in the search conducted in PubMed and Web of Science. After the screening, 102 articles unrelated to the proposed theme were excluded. Thus, 10 articles were analyzed by the eligibility and exclusion criteria, and included in this systematic review. CONCLUSION: The information resulting from the analysis of the reviewed articles suggests that mild, but not definitive deficits in cognitive performance might be masked by insignificant disparities in studies comparing insomniac individuals with normal sleepers. This shortcoming can be circumvented by larger and better-characterized samples, together with optimized methodological control of factors which might otherwise result in confounding variations among participants.

INTRODUÇÃO: A insônia é o distúrbio do sono mais comum: relatórios recentes estimam que 25-30% dos adultos sofrem episódios de insônia, enquanto 10% sofrem de distúrbio do sono suficientemente grave para cumprir os critérios de diagnóstico para insônia. Além disso, pouco se sabe sobre os mecanismos, causas, evolução clínica, e consequências desta doença crónica altamente prevalente. Mais de 30 estudos foram publicados sobre o assunto, mas apenas uma pequena proporção encontrou diferenças entre os indivíduos com e sem insônia, por exemplo, na memória de trabalho. OBJETIVO: Examinar as evidências sobre as diferenças entre adultos insones e normais no desempenho da memória de trabalho. MÉTODOS: A pesquisa foi realizada usando uma pesquisa avançada no ISI Web of Science e MEDLINE/PubMed com os termos "sleep", "insônia" e "memória de trabalho" como os principais descritores, que foram cruzados com as seguintes palavras-chave: "testes psicológicos", "neuropsicologia" e "performance". RESULTADOS: Um total de 132 artigos foram identificados na pesquisa realizada no PubMed e Web of Science; 20 duplicações foram excluídas. Após a triagem, 102 artigos foram excluídos, que não estavam relacionadas com o tema proposto. Assim, 10 artigos foram selecionados por critérios de elegibilidade e de exclusão, e incluídos na revisão sistemática. CONCLUSÃO: As descobertas relatadas em nosso estudo sugerem que os deficits leves mas não permanentes de desempenho cognitivo podem ser mascarados por disparidades insignificantes em estudos que comparam indivíduos com insônia com pessoas com sono normal. Tal deficiência pode ser contornada pela análise de amostras maiores e mais bem caracterizadas, em conjunto com o controle metodológico otimizado de fatores que potencialmente podem incorrer em variações entre os participantes.

Chronic effects of aerobic exercise on panic disorder: a systematic review of randomized and non-randomized trials / Efeitos crônicos do exercício aeróbio sobre o transtorno do pânico: uma revisão sistemática de ensaios clínicos randomizados e não-randomizados

BACKGROUND: In general, most studies have supported an association between the acute effects of exercise and a reduced state anxiety, but failed to completely explain the relationship between the chronic effect of exercise and anxiety traits. OBJECTIVE: The aim of this study was to systematically review the literature regarding the chronic effect of exercise on symptoms associated with panic disorder. METHODS: The studies were retrieved from a MEDLINE/PubMed, ISI Web of Knowledge and SciELO. We adopted PICOS’s strategy recommended to determine the eligibility criteria. The survey was conducted using an advanced search in the ISI Web of Science and MEDLINE / PubMed with MeSH terms and Entry Terms for the keywords “Panic Disorder” basis and “Exercise”. Boolean operators “AND” and “OR” were used separately or in combination. Two independent researchers performed the selection of studies; in case of disagreement they sought a consensus on the selection. RESULTS: A total of 265 articles were identified: 199 articles from PubMed/Medline, 63 articles from ISI Web of Science and 3 articles by manual searches. Thus, 31 articles were analyzed by the eligibility criteria and the exclusion criteria, a total of five studies included in the systematic review. CONCLUSION: The regular practice of aerobic exercise seems to be an appropriate intervention to promote improvements in the severity of anxiety symptoms in PD patients.

INTRODUÇÃO: Em geral, grande parte dos estudos indicam a existência de uma associação entre os efeitos agudos do exercício aeróbio e um estado de ansiedade reduzida; no entanto, estes estudos não conseguem elucidar completamente a relação entre o efeito crônico do exercício aeróbio e traços de ansiedade. OBJETIVO: O objetivo deste estudo foi revisar sistematicamente a literatura sobre o efeito crônico do exercício sobre sintomas associados com transtorno do pânico. MÉTODOS: Os estudos foram recuperados de: MEDLINE/PubMed, ISI Web of Knowledge e SciELO. Adotamos a estratégia PICOS para determinar os critérios de elegibilidade. A estratégia de busca foi realizada utilizando uma pesquisa avançada no ISI Web of Science, MEDLINE/PubMed e SciELO com os seguintes termos: “Transtorno de Pânico” e “Exercício”. Operadores booleanos AND e OR foram utilizados para combinação dos termos. A seleção dos estudos foi realizada por dois pesquisadores independentes que, em caso de desacordo, procuraram um consenso sobre a seleção. RESULTADOS: Foram identificados um total de 265 artigos: 199 artigos do PubMed/Medline, 63 artigos do ISI Web of Science e 3 artigos através de pesquisas manuais. Assim, 31 artigos foram analisados pelos critérios de elegibilidade e os critérios de exclusão, sendo que um total de cinco estudos foram incluídos na revisão sistemática. CONCLUSÃO: A prática regular de exercício aeróbio parece ser uma intervenção apropriada para promover a melhoria da gravidade dos sintomas de ansiedade em pacientes com transtorno de pânico.